Human papilloma virus infection in head and neck cancer;Infektionen mit humanen papillomaviren bei kopfhalskarzinomen

Deutsches Arzteblatt International

Volumn 110, Issue 11, 2013, Pages 184-190

  Tribius, Silke ^a   Hoffmann, Markus ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; DISEASE ASSOCIATION; DISEASE COURSE; HEAD AND NECK CANCER; HUMAN; IMMUNIZATION; OVERALL SURVIVAL; PAPILLOMAVIRUS INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); CAUSALITY; COMORBIDITY; EVIDENCE BASED MEDICINE; GERMANY; HEAD AND NECK NEOPLASMS; INTERNATIONAL COOPERATION; META ANALYSIS; MORTALITY; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; PREVALENCE; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

CAUSALITY; COMORBIDITY; EVIDENCE-BASED MEDICINE; GERMANY; HEAD AND NECK NEOPLASMS; HUMANS; INTERNATIONALITY; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRECANCEROUS CONDITIONS; PREVALENCE; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84988285630     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2013.0184     Document Type: Article

References (40)

1. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre): Human Papillomavirus and Related Cancers in Germany. Summary Report 2010. www.who.int/hpvcentre. Last accessed 31 October 2012
2. Globocan: Cancer incidence and mortality worldwide. 2008; http://globocan.iarc.fr/. Last accessed 24 September 2012
3. Blot WJ, McLaughlin JK, et al.: Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988; 11: 3282-7
4. Brennan JA, Boyle JO, Koch WM, et al.: Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. New Engl J Med 1995; 332: 712-7
5. Ang KK, Sturgis EM: Human Papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma. Sem Rad Onc 2012; 22: 128-42
6. Conway DI, Stockton DL, Warnakulasuriya KA, et al.: Incidence of oral and oropharyngeal cancer in United Kingdom (1990-1999)-recent trends and regional variation. Oral Oncol 2006; 42: 586-92
7. Braakhuis BJ, Visser O, Leemans CR: Oral and oropharyngeal cancer in the Netherlands between 1989 and 2006: increasing incidence, but not in young adults. Oral Oncol 2009; 45: e85-9
8. National Cancer Institute. Surveillance epidemiology and end results cancer statistics 1992-2009 (SEER 13). http://seer.cancer.gov/ faststats. Last accessed 17 July 2012
9. Blomberg M, Nielsen A, Munk C, et al.: Trends in head and neck cancer incidence in Denmark, 1978-2007: focus in human papillomavirus associated sites. Int J Cancer 2011; 129: 733-741
10. Hammerstedt L, Dahlstrand H, Lindquist D, et al.: The incidence of tonsillar cancer in Sweden is increasing. Acta Otolaryngol 2007; 127: 988-92
11. Guntinas-Lichius O, Wendt T, Buentzel J, et al.: Head and neck cancer in Germany: A site-specific analysis of survival of the Thuringian cancer registration database. J Cancer Res Clin Oncol 2010; 136: 55-63
12. Termine N, Panzarella V, Falaschini S, et al.: HPV in oral squamous cell carcinoma vs. head and neck squamous cell carcinoma biopsies: A meta-analysis (1988-2007). Ann Oncol 2008; 19: 1681-90
13. Kreimer AR, Clifford GM, Boyle P, et al.: Human papillomavirus types in head and neck squamous cell carcinomas worldwide: A systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14: 467-75
14. Hoffmann M, Ihloff AS, Görögh T, et al.: p16(INK4a) overexpression predicts translational active human papillomavirus infection in tonsillar cancer. Int J Cancer 2010; 127: 1595-602
15. Hoffmann M, Tribius S, Quabius ES, et al.: HPV DNA, E6(.∗)I-mRNA expression and p16(INK4A) immunohistochemistry in head and neck cancer-How valid is p16(INK4A) as surrogate marker? Cancer Lett 2012; 323: 88-96
16. Holzinger D, Schmitt M, Dyckhoff G, Brenner A, Pawlita M, Bosch FX: Viral RNA pattern and high viral load reliably define oropharynx carcinomas with active HPV16 involvement. Cancer Res 2012; 72: 4993-5003
17. Chaturvedi AK, Engels EA, Pfeiffer RM, et al.: Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29: 4294-301
18. D'Souza G, Agrawal Y, Halpern J, Bodison S, Gillison ML: Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis 2009; 199: 1263-9
19. Gillison ML, Zhang Q, Jordan R, et al.: Tobacco smoking and increas - ed risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol 2012; 30: 2102-11
20. Posner MR, Lorch JH, Goloubeva O, et al.: Survival and human papillomavirus in oropharynx cancer in TAX 324: A subset analysis from an international Phase III trial. Ann Oncol 2011; 22: 1071-7
21. Rischin D, Young RJ, Fisher R, et al.: Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III tria. J Clin Oncol 2010; 28: 4142-8
22. Ang KK, Harris J, Wheeler R, et al.: Human papillomavirus and survival of patients with oropharyngeal cancer. New Engl J Med 2010; 363: 24-35
23. Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J: Effect of HPV-associated p16INK4A expression on Response to Radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2012; 27: 1992-8
24. Fakhry C, Westra WH, Li S, et al.: Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100: 261-9
25. Gilbert J, Murphy B, Dietrich MS, et al.: Phase 2 trial of oxaliplatin and pemetrexed as induction regimen in locally advanced head and neck cancer. Cancer 2012; 118: 1007-13
26. Jo S, Juhasz A, Zhang K, et al.: Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial. Anticancer Res 2009; 29: 1467-74
27. Syrjänen K, Syrjänen S, Pyrhönen S: Human papilloma virus (HPV) antigens in lesions of laryngeal squamous cell carcinomas. ORL J Otorhinolaryngol Relat Spec 1982; 44: 232-34
28. Gillison ML, Koch WM, Capone RB, et al.: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92: 709-20
29. Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM: Human Papillomavirus positive squamous cell carcinoma of the oropharynx: A radiosensitive subgroup of head and neck carcinoma. Cancer 2001; 92: 805-13
30. Tribius S, Ihloff AS, Rieckmann T, Petersen C, Hoffman M: Impact of HPV status on treatment of squamous cell cancer of the oropharynx: what we know and what we need to know. Cancer Lett 2011; 304: 71-9
31. Jemal A, Bray F, Center MM, et al.: Global Cancer Statistics. CA Cancer J Clin 2011; 61: 69-90
32. Trotti A, Pajak TF, Gwede CK, et al.: TAME: Development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol 2007; 8: 613-24
33. FUTURE I/II Study Group: Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010; 341: c3493
34. Paavonen J, Naud P, Salmerón J, et al.: HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by onco - genic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374: 301-14
35. Giuliano AR, Palefsky JM, Goldstone S, et al.: Efficacy of quadriva - lent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011; 364: 401-11
36. de Sanjosé S, Diaz M, Castellsagué X, et al.: Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: A meta-analysis. Lancet Infect Dis 2007; 7: 453-9
37. Bosch FX, Burchell AN, Schiffman M, et al.: Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008; 26 Suppl 10: K1-16
38. Giuliano AR, Tortolero-Luna G, Ferrer E, et al.: Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine 2008; 26 Suppl 10: K17-28
39. D'Souza G, Dempsey A: The role of HPV in head and neck cancer and review of the HPV vaccine. Prev Med 2011; 53 Suppl 1: 5-11
40. Hartwig S, Syrjänen S, Dominiak-Felden G, et al.: Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: A review. BMC Cancer 2012; 12: 30